Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression

Short title: GLP-1 receptor agonists and blood pressure reduction

Frederick Berro Rivera, MD;¹ Grace Nooriza O. Lumbang, MD;² Danielle Rose Magno Gaid, MD;² Linnaeus Louisse A. Cruz, MD;³ John Vincent Magalong, MD;³ Nathan Ross B. Bantayan, BSc;³ Kyla M. Lara-Breitinger, MD;⁴ Martha Gulati, MD MS;⁴ George Bakris, MD⁶

¹Department of Medicine, Lincoln Medical Center, New York, NY, USA
²Cebu Institute of Medicine, Cebu City, Philippines
³University of the Philippines College of Medicine, Manila, Philippines
⁴Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, (MN), USA
⁵Department of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA
⁶Department of Medicine, University of Chicago, Chicago (IL), USA

Abstract Word Count: 250 Manuscript word count: 5,857

Funding: None
Disclosures:
MG: Consultant Fees/Honoraria: Esperion, Novartis, and Boehringer Ingelheim
Research/Research Grants: Congressionally Directed Medical Research Program-Department of
Defense (WARRIOR study)

Address for Correspondence:

George Bakris, MD University of Chicago Goldblatt Pavilion, 5841 S Maryland Ave, Chicago, IL 606337 Email: gbakris@gmail.com

ABSTRACT

Background. The cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP lowering effect by GLP1-RAs.

Methods. A comprehensive database search for placebo-controlled randomized controlled trials (RCTs) on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with mean difference (MD) in millimeters mercury (mmHg) and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic and diastolic BP. Subgroup analyses and meta-regression were done to account for covariates.

Results. Compared to placebo, GLP-1RAs modestly reduced SBP (semaglutide: MD -3.40, [95% CI -4.22 to -2.59, p<0.001], liraglutide: MD -2.61, [95% CI -3.48 to -1.74, p<0.001], dulaglutide: MD -1.46, [95% CI -2.20 to -0.72, p<0.001] and exenatide: MD -3.36, [95% CI - 3.63 to -3.10, p<0.001]). This benefit consistently increased with longer treatment duration. Established people with type 2 diabetes experienced less SBP lowering with semaglutide. DBP reduction was only significant in the exenatide group (MD -0.94, [95% CI -1.78 to -0.1], p=0.03). Among semaglutide cohorts, mean change in hemoglobin A1c and mean change in body mass index were directly associated with SBP reduction.

Conclusion. Patients on GLP-1RA experienced modest SBP lowering compared to placebo. Only exenatide reduced DBP. Further studies are needed to clarify the mechanisms and the clinical benefit of GLP-1RA effects in BP reduction.

Keywords: Glucagon-like peptide-1 receptor agonists, GLP-RA, blood pressure, semaglutide, liraglutide, exenatide, dulaglutide

Abbreviations

BP = blood pressure BMI=body mass index DBP = diastolic blood pressure GLP-1RA = glucagon-like peptide-1 receptor agonists MD= mean difference RCTs = randomized controlled trials SBP = systolic blood pressure T2DM= type 2 diabetes mellitus

INTRODUCTION

In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a first-line drug in the treatment of type 2 diabetes mellitus (T2DM).¹ GLP-1RAs have also been found to significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM, as demonstrated by multiple large cardiovascular outcome trials (CVOTs).² Recently, the STEP-HFpEF (Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) trials, found that semaglutide led to improvements in symptoms, physical limitations, and exercise function in patients with heart failure, as well as decreased the risk of MACE in overweight and obese patients.^{3, 4} The available evidence demonstrates the significance of GLP-1 receptor agonists in the treatment of obesity and the reduction of cardiovascular risk in patients with type 2 diabetes mellitus.^{5, 6} The cardiovascular benefits provided by GLP-1RAs are found to be significant, independent of its effects on glycemic control.⁷ However, the specific mechanisms underlying the cardiovascular protection provided by GLP-1RAs have not yet been fully elucidated. One such pathway may be the reduction of blood pressure, a well-known CV risk factor.^{8,9} GLP-1 receptors are found in the hypothalamus and brainstem, the heart and vasculature, and the kidneys, suggesting multiple potential mechanisms that underlie the blood pressure-lowering effects of GLP1-RAs, independent of their effect on glycemic control.^{10, 11} Among these include, but are not limited to, inhibition of sympathetic nerve excitation, reduction of vascular inflammation and arterial stiffness, and promotion of natriuresis and diuresis.¹¹ Previous studies have shown that GLP-1RAs reduce blood pressure by as much as 2-3 mmHg, with systolic BP being lowered more than diastolic BP.^{12, 13} In subsequent meta-analyses, liraglutide and semaglutide have been demonstrated to

provide a significant reduction in systolic blood pressure.^{14, 15} Nevertheless, the significance of the effect on BP lowering by GLP1-RAs overall and across different subgroups remains inconclusive, and thus there is a need to bridge existing knowledge gaps with the latest evidence from recent trials in GLP-1RA use.

In this study, we conducted a thorough systematic review and meta-analysis of RCTs on the four widely used GLP-1RAs (Semaglutide, Liraglutide, Exenatide and Dulaglutide). We aim to determine the efficacy of GLP-1RA in reducing SBP and DBP across different GLP-1RAs. Subgroups based on dose, treatment duration, baseline mean SBP and DM status, as well as regression analyses were done to account for covariates.

METHODS

This study was reported under the Preferred Reporting Items for a Review and Meta-Analysis (PRISMA)¹⁶, and the checklist¹⁷ was followed (**Figure S1**). Certainty of evidence was rated using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) framework.¹⁸ This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO)¹⁹, with the identification number CRD42024497765.

Data Sources and Searches

The literature search was performed using PubMed/MEDLINE, Ovid/Embase, and clinicaltrial.gov databases from database inception until December 2023. Search terms included "glucagon-like peptide-1 receptor agonists", "GLP-1 agonist", "GLP-1RA", "semaglutide", "dulaglutide", "exenatide", "liraglutide", "placebo", "blood pressure", "systolic blood pressure" "diastolic blood pressure", "randomization", "clinical trials", "intervention studies" and

synonyms. Citations of selected articles and any relevant studies that evaluated GLP-1RA and blood pressure reduction were reviewed. After removing duplicates, records were reviewed at the title and abstract level, followed by the screening of full text based on our study criteria.

Study Selection

Eligible phase II or phase III, double-blind randomized controlled trials (RCTs) comparing treatment with GLP-1RA with placebo in adult patients aged 18 years and above were included. Moreover, the studies must have reported baseline SBP and DBP and blood pressure reduction in weighted mean difference. Studies must have reported the mean change in weight, mean change in hemoglobin A1c, and mean change in body mass index. Furthermore, studies must have data on the baseline mean SBP and DBP and must mention the diabetes status of the cohort. Studies were excluded if (1) they did not report a control arm, (2) there was an active comparator, and (3) mean change was not reported. Other agents such as albiglutide, lixisenatide, efpeglenatide, were excluded because cardiovascular outcomes are not well established with these agents. We also excluded RCTs with participants younger than 18, and those reporting interim or post hoc analysis. Cross-over trials were also excluded due to the nature of the outcomes considered. Review articles, case reports, letters to the editor, commentaries, proceedings, laboratory studies, and other non-relevant studies were excluded as well.

Data Extraction

Key participant and intervention characteristics and reported data on efficacy outcomes were extracted independently by two investigators (GOL and DMG) using standard data extraction templates. Any disagreements were resolved by discussion or, if required, by a third author (FBR). Data on the following variables were extracted: first author's name, year of publication,

journal, study phase, interventional and control treatments, randomization method, analysis tool, number of randomized patients, and demographic and clinical data (e.g., age, sex). In case of uncertainties regarding the study data, we contacted the authors of the specific study for additional information. Quality assessment was performed independently by two review authors using the Revised Cochrane risk-of-bias tool for randomized trials.

Outcome Measures

The primary endpoint of this meta-analysis and meta-regression was the weighted mean difference (MD) in SBP and DBP. Additionally, subgroup analyses were performed for applicable studies on the (1) duration of treatment in weeks, (2) dose, (3) mode of administration, (4) mean baseline SBP, and (5) DM status of the cohorts.

Bias Assessment

All included studies reported a central randomization process, and outcomes were objectively determined. The included studies reported all primary and secondary outcomes as pre-specified in their protocols, so the risk of bias for selective reporting was judged as low. Three authors (JM, DMG, and GOL) independently assessed the risk of bias based on the Cochrane Risk of Bias Tool (**Figures S2**) for studies that fulfilled the inclusion criteria. Disagreements between the reviewers were resolved by consensus.

Statistical Analysis

We pooled all estimates using a random effects model based on the restricted maximum likelihood (REML) model. Effect sizes were expressed using mean differences with 95% confidence intervals (CIs). Funnel plot and Egger test were used for estimation of publication

bias. For all outcomes, the significance level was set at a p-value of <0.05 or 95% CI not including 1. Both Cochran's Q and Higgins and Thompson's I2 statistics were generated to describe the heterogeneities among the studies. We calculated the I^2 statistics (0–100%) to explain the between-study heterogeneity, with $I^2 \le 25\%$ suggesting acceptable homogeneity, 25% $< I^2 \le 75\%$ suggesting moderate heterogeneity, and $I^2 > 75\%$ suggesting high heterogeneity. Forest plots were used to plot the effect size, either for each study or overall. Publication bias was evaluated by graphical inspection of funnel plot; estimation of publication bias was quantified by means of Egger linear regression test. Meta-regression analysis was performed, reporting results as *P* value. Stata version 18 (*StataCorp, College Station, TX*) was used to conduct the included studies' meta-analyses and meta-regression.

RESULTS

A literature search through December 2023, yielded 4,178 potentially relevant references on GLP-1RA. (**Figure S1**). Of these, 1,156 duplicates were removed. A total of 1,221 studies with unrelated interventions, outcomes, populations, non-original data (e.g., meta-analysis or review), descriptive or observational study design, and study protocols were excluded. 635 articles were removed for not meeting the eligibility criteria. The remaining 66 related studies were retrieved as full-text publications for detailed evaluation. Finally, 63 studies were included in the final meta-analysis. 53,072 participants were included, 32, 113 (60.51%) of which are females. The rest of study characteristics are shown in **Table 1**. Majority of the RCTs were multinational and sponsored by drug companies.

Liraglutide had the most RCTs with 30 studies²⁰⁻⁴⁹ having it as the intervention. There were 16 RCTs^{3, 4, 50-63} done for Semaglutide and 5 for dulaglutide.⁶⁴⁻⁶⁸ Exenatide had 12 RCTs.⁶⁹⁻⁸⁰ Thirty-eight (38) RCTs^{21, 24, 26, 29, 31, 33, 36-38, 41, 43, 44, 47, 51, 55-60, 62, 64-70, 72, 74, 76-78, 80, 81} were done

exclusively among patients with DM. Among these RCTs, majority^{21, 24, 26, 41, 43, 44, 47, 51, 55, 60, 64, 68, 74, 76-78, 80-82} enrolled exclusively T2DM patients. Seven (7) RCTs^{20, 25, 27, 49, 50, 79, 83} enrolled both patients with or without diabetes. The remaining eighteen RCTs did not include patients with DM, three (3)^{34, 39, 40} of which included exclusively patients with prediabetes.

Among the RCTs in this study, 61 have data for SBP^{3, 4, 20, 21, 23-29, 31-46, 48-51, 53-81, 83}. Conversely, 55 RCTs have data for DBP. The method of BP measurement varied among the RCTs. Five (5) RCTs^{29, 37, 41, 66, 72} used continuous or 24-hour ambulatory blood pressure monitoring (ABPM). Among these, Bojer et al. (2021)²⁹ performed orthostatic BP measurement with supine and standing BP readings. The remaining 58 RCTs did not employ continuous BP monitoring, but instead utilized routine BP measurements, which were performed at specified intervals; methodology varied among these studies: 22 RCTs^{21, 28, 31, 34, 35, 38, 44, 46, 47, 50, 51, 53-55, 57, 61, 64, 65, 68, 75, 78, 79} used seated blood pressure, Gullaksen et al. (2023)⁶² used supine BP, Wadden et al. (2019)⁴⁸ used standing BP, Dushay et al. (2012)⁷¹ did not mention the posture of the patient but used a Dynamap automated monitoring device, and 33 other RCTs did not explicitly mention the method of routine BP measurement.

Forty-four (44) RCTs included patients with CKD, but many trials employed a varying cutoff eGFR to exclude patients with more severe CKD: Klausen et al., 2022^{73} excluded patients with eGFR = 50 mL/min/1.73 m² and/or microalbuminuria. Gullaksen et al., 2023^{62} excluded patients with eGFR < 45 mL/min/1.73 m². STEP 6⁵⁰ excluded patients with eGFR < 30 mL/min/1.73 m² if the patient has T2DM (only in Japan) but excluded patients with eGFR < 15 mL/min/1.73 m² if the patient has no T2DM. Eighteen (18) RCTs^{20, 21, 25, 41, 42, 46, 49, 51, 55-58, 64-66, 77-79} excluded patients with eGFR < 30 mL/min/1.73 m²; among these 18 trials, PIONEER 5⁵⁵ specifically excluded patients with rapidly progressive renal disease or known nephrotic

albuminuria (> 2200 mg/24 hr or > 2200 mg/g), Ferdinand et al., 2014⁶⁶ also excluded patients with eGFR = 30 mL/min/1.73 m², DURATION-7⁷⁷ further excluded patients on metformin with eGFR < 60 mL/min/1.73 m2, serum creatinine >/= 1.5 mg/dL in men, or >/= 1.4 mg/dL in women. Six (6) RCTs^{3, 4, 52-54, 63} excluded patients with eGFR < 15 mL/min/1.73 m². Ten (10) RCTs did not mention CKD or renal disease as an exclusion criterion. Idorn et al. (2016)³³ specifically included patients with end-stage renal disease. Six (6) RCTs^{24, 26, 27, 35, 39, 67} used exclusively a serum creatinine (sCr) level as a cutoff to exclude patients with CKD, with three (3) RCTs^{26, 27, 39} excluding patients with sCr > 150 µmol/L; of these 3, Larsen et al., 2017³⁹ excluded patients with macroalbuminuria. The 3 other RCTs have sCr cutoff values as follows: ELEGANT²⁴ excluded patients with sCr > 130 µmol/L, Kuhadiya et al. (2016)³⁵ excluded patients with sCr > 1.5 mg/dL, and Grunberger et al. (2012)⁶⁷ excluded patients with sCr >/= 1.5 mg/dL in men or >/= 1.4 mg/dL in women. However, using a serum creatinine value as an exclusion criterion can end up including patients with CKD despite having a normal sCr, which tends to occur in the elderly.⁸⁴

Eighteen (18) RCTs excluded patients with CKD, twelve $(12)^{23, 29, 36-38, 43, 47, 59, 60, 75, 80, 83}$ of which used an eGFR cutoff of < 60 mL/min/1.73 m², while six (6)^{31, 34, 44, 48, 70, 76} did not use an eGFR cutoff but excluded patients with known CKD. For the remaining trial, which is Astrup et al., 2009^{28} , it was not clear if CKD patients are excluded since "major medical conditions" was an exclusion criterion, but it did not explicitly mention as to whether CKD is a major medical condition.

The reporting of baseline blood pressure varied among RCTs. Among them, nine $(9)^{36, 38, 46, 52, 54, 59, 60, 71, 78}$ RCTs reported a mean baseline SBP that included all treatment groups. Of these 9 RCTs, five $(5)^{46, 52, 54, 71, 78}$ have a mean SBP of 120-129 mmHg at baseline, three $(3)^{36, 59, 60}$ have a mean baseline SBP 130-139, and only one³⁸ have mean baseline SBP >/= 140. Forty-

five (45) studies did not report a mean across all treatment groups but reported means of each treatment arm. Of these 45 RCTs, two (2) have treatment arms with mean SBPs belonging to different ranges. Conversely, the other 43 RCTs have either only 1 treatment arm or have multiple treatment arms with mean SBPs belonging to the same range: $18 \text{ RCTs}^{20, 21, 23, 28, 32, 35, 39}$, 40, 42, 45, 53, 63, 66, 67, 69, 79, 83 have a treatment arm with mean SBP of 120-129 mmHg at baseline, 24 RCTs^{3, 4, 24, 25, 27, 29, 37, 43, 44, 47-51, 56, 62, 64, 65, 70, 72, 74, 75, 77, 80 have a treatment arm with mean baseline SBP 130-139, and only one³¹ have a treatment arm with mean baseline SBP >/= 140. The remaining nine (9)^{26, 33, 41, 55, 57, 58, 61, 68, 73} RCTs did not mention any baseline SBP.}

Systolic blood pressure reduction

<u>Semaglutide</u>

Semaglutide significantly reduced SBP with a MD of -3.40, (95% CI, -4.22 to -2.59), p<0.001, (I^2 87.78; p<0.001). Subgroup analysis based on the mode of administration showed significant SBP reduction for both oral (MD: -4.06, 95% CI (-5.19 to -2.93), p<0.001) and subcutaneous (MD: -3.40, 95% CI (-4.13 to -2.31), p<0.001) semaglutide. (See figure 1) Subgroup analysis based on treatment duration showed significant SBP reduction for patients who received treatment for more than 26 weeks (MD: -4.23, 95% CI (-5.02 to -3.44), p<0.001) compared to those who received the treatment for 26 weeks or less (MD: -0.65, 95% CI (-1.13 to -0.16), p<0.001), p-interaction<0.001). (See figure 2) Subgroup analysis for subcutaneous Semaglutide based on dosing showed significant SBP reduction for patients who received a dose of >1 mg (MD: -4.57, 95% CI (-5.89 to -3.26), p<0.001) compared to those who received a dose of 1 mg or less (MD: -2.52, 95% CI (-3.44 to -1.59), p<0.001), (p-interaction NS). (See figure S3) Subgroup analysis based baseline mean SBP showed significant SBP reduction for patients who had a mean SBP between 120-129 mmHg (MD: -5.19, 95% CI (-7.28 to -3.09), p<0.001)

compared to those who had a mean SBP between 130-139 mmHg (MD: -2.66, 95% CI (-3.84 to - 1.48), p<0.001), (p-interaction<0.04). (See figure 3) Subgroup analysis based on DM status showed significant reduction in SBP among those without DM (MD: -4.60, 95% CI -5.61 to - 3.59, p<0.01) versus among those with DM (MD: -2.15, 95% CI -3.14 to -1.15, p<0.01), (p-interaction <0.01). (See figure 4)

<u>Liraglutide</u>

Liraglutide significantly reduced SBP with a MD of -2.61 (95% CI, -3.48 to -1.74), p<0.001. Subgroup analysis based on treatment duration showed significant SBP reduction for both those who received treatment for more than 24 weeks (MD: -2.35, 95% CI (-3.44 to -1.25), p<0.001) and to those who received the treatment for 24 weeks or less (MD: -3.11, 95% CI (-4.40 to -1.83), p<0.001), p-interaction<NS). (**See figure 5**) Subgroup analysis based on dosing showed similar significant SBP reduction for patients who received a dose of >1.8 mg (MD: -2.65, 95% CI (-4.40 to -0.89), p<0.001) and to those who received a dose of 1.8 mg or less (MD: -2.68, 95% CI (-3.46 to -1.91), p<0.001), p-interaction NS). (**See figure 54**) Subgroup analysis based on the mean baseline SBP showed significant SBP reduction for patients who had baseline SBP of 120-129 mmHg (MD: -2.64, 95% CI (-3.36 to -1.93), p<0.001) than those who had a mean baseline SBP of 130-139 mmHg (MD: -0.98, 95% CI (-3.03 to 1.07), p=0.035). (**See figure S5**) Subgroup analysis based on DM status showed significant reduction in SBP for both those without DM (MD: -2.92 mmHg, 95% CI -4.54 to -1.30, p<0.01) versus among those with DM (MD: -2.57, 95% CI -3.39 to -1.76, p<0.01), (p-interaction NS). (**See figure S6**)

<u>Dulaglutide</u>

Dulaglutide significantly reduced systolic blood pressure with a MD of -1.46 (95% CI, -2.20 to -0.72), p<0.001. Subgroup analysis based on treatment duration both showed significant SBP reduction for patients who received treatment for 24 weeks or more (MD: -1.14, 95% CI (-2.09 to -0.19), p<0.001) compared to those who received the treatment for less than 24 weeks (MD: -2.00 95% CI (-2.20 to -0.72), p<0.001), p-interaction NS). (See figure 6) Subgroup analysis based on dosing showed significant SBP reduction for patients who received a dose of 1 mg or more (MD: -1.90, 95% CI (-2.92 to -0.88), p<0.001) compared to those who received a dose of 1 mg or more (MD: -1.90, 95% CI (-2.92 to -0.88), p<0.001) compared to those who received a dose of less than 1 mg (MD: -0.84, 95% CI (-1.81 to -0.13), p<0.001), p-interaction NS). (See figure S7) Subgroup analysis based on the mean baseline SBP showed significant SBP reduction for patients who had baseline SBP of 120-129 mmHg (MD: -2.11, 95% CI (-2.79 to -1.43), p<0.001) than those who had a mean baseline SBP of 130-139 mmHg (MD: -1.11, 95% CI (-2.28 to 0.05), p=0.06). (See figure S8)

<u>Exenatide</u>

Exenatide significantly reduced SBP with a MD of -3.36, (95% CI, -3.63 to -3.10), p<0.001. Subgroup analysis based on treatment duration both showed significant SBP reduction for patients who received treatment for 24 weeks or more (MD: -3.37, 95% CI (-3.63 to -3.11), p<0.001) compared to those who received the treatment for less than 24 weeks (MD: -1.63, 95% CI (-5.63 to 2.36), p=0.42), p-interaction NS). (See figure S9) Subgroup analysis based on the mean baseline SBP showed similar significant SBP reduction for patients who had baseline SBP of 120-129 mmHg (MD: -2.75, (95% CI -5.22 to -0.27, p=0.03) and those who had a mean baseline SBP of 130-139 mmHg (MD: -3.37, 95% CI (-3.73 to -3.00), p=0.00). (See figure 10)

Diastolic blood pressure reduction

Semaglutide (MD: -0.72, (95% CI, -1.54 to -0.10, p=0.08), liraglutide (MD: -0.23 (95% CI, -0.59 to 0.12, p=0.68), and dulaglutide (MD: 0.27 (95% CI, -0.05 to 0.59, p=0.10) failed to reduce DBP. Exenatide modestly reduced DBP (MD: -0.94 (95% CI, -1.78 to -0.10, p=0.03.

<u>Meta-regression analysis</u>

Meta-regression analysis revealed that mean change in weight (p=0.02, tau² 3.047, R² analog=37.65), (**Figure S11**) mean change in A1c (p=0.010, tau² 2.989, R² analog=28.27) (**Figure S12**) and mean change in BMI (p=0.00, tau² 0.165, R² analog=92.57) (**Figure S13**) were associated with the treatment effect for SBP reduction for semaglutide. For exenatide, only the mean change in A1c affected the treatment effect (p=0.03, tau² 9.8, R² analog=80.20). For dulaglutide, mean change in A1c (p=0.002, tau² 0.1308, R² analog=81.80) and mean change in weight (p=0.00, tau² 6.6, R² analog=100.00) affected the treatment effect. These factors did not affect the treatment effect for liraglutide.

DISCUSSION

We completed a detailed meta-analysis and meta-regression on the efficacy of the four common GLP-1RAs in reducing blood pressure. We established that GLP-1RAs reduced SBP by 1.46 to 3.40 mmHg. Semaglutide, liraglutide, dulaglutide and exenatide all reduced SBP to a certain degree. Through regression analyses, we established that mean change in weight, mean change in A1c, and mean change in BMI were directly associated with SBP reduction. Subgroup analyses done between dose and route of semaglutide and its effect on SBP revealed statistically significant, but clinically modest SBP reduction that was comparable between two dose groups of semaglutide (high vs low dose regimen) and between two different routes of administration (oral vs subcutaneous). Those with lower mean baseline SBP experienced greater BP lowering

effect. Furthermore, greater SBP reduction was noted among patients who received longer duration of semaglutide treatment compared to those who had shorter treatment duration. Comparing patients with vs without T2DM, we found that semaglutide modestly reduced SBP with statistical significance among those without T2DM compared to those with T2DM, while liraglutide modestly reduced SBP in both cohorts. Contrary to its promising effects in SBP lowering, GLP-1RA has very minimal to no effect on DBP. Of the four GLP-1RAs, only exenatide reduced DBP which was more pronounced to those without T2DM.

SBP reduction, Semaglutide

We established that semaglutide demonstrated a statistically significant but clinically modest reduction in SBP compared to placebo by 3.40 mmHg. This has been demonstrated by multiple large RCTs that enrolled > 1,000 participants such as PIONEER 6^{56} , SELECT⁴, and Wilding et al. $(2021)^{63}$, as well as other RCTs that enrolled hundreds such as STEP 2^{51} , STEP 6^{50} , OASIS 1^{54} , and O'Neil et al. $(2018)^{61}$. There was substantial heterogeneity in our results (I2 = 89.18%), and this can be explained by some RCTs in our study, such as STEP 5^{53} , STEP HFpEF³, and SUSTAIN 1^{57} , which did not demonstrate a statistically significant reduction in SBP. The results of our study were consistent with a recent meta-analysis done by Kennedy et al. (2023)⁸⁵, which included 6 RCTs with 4,744 participants; this meta-analysis showed that semaglutide decreased SBP by 4.83 mmHg (95% CI, -5.65 to -4.02).

The route of administration of semaglutide had no significant effect on SBP reduction, as our study showed that orally administered semaglutide reduced SBP by 4.06 mmHg whereas subcutaneous administration reduced SBP by 3.22 mmHg (p interaction NS). This is consistent with an RCT done by Davies et al. (2017)⁵⁹, which compared subcutaneous semaglutide 1 mg to varying doses of oral semaglutide (2.5 to 40 mg); a similar reduction in SBP was observed

between the two routes: 5.7 mmHg with subcutaneous semaglutide vs 5.4 to 7.8 mmHg among different oral semaglutide doses. Notedly, oral semaglutide differed from subcutaneous administration in terms of the dosage used and frequency of administration: oral semaglutide is given daily with a higher dose, whereas subcutaneous semaglutide is administered weekly.

Prolonged administration of semaglutide had a greater impact on SBP, thereby suggesting a duration-dependent effect: there was a reduction of SBP by 4.25 mmHg among trials that administered semaglutide for > 26 weeks, compared to trials that administered semaglutide for </= 26 weeks, with SBP reduction of 0.55 mmHg. Four RCTs that administered semaglutide for less than 26 weeks had no significant reduction in SBP.^{55, 59, 60, 62} On the other hand, SBP reduction among RCTs that administered semaglutide for > 26 weeks varied, as some trials^{3, 53, 57} failed to demonstrate significant SBP reduction but most other trials with duration > 26 weeks^{4, 50, 51, 54, 56, 61, 63 were able to demonstrate this treatment effect.}

There was a marked reduction in SBP with higher doses of subcutaneous (SC) semaglutide compared to lower doses. O'Neil et al.⁶¹ successfully demonstrated a significant SBP reduction (mean -4.49 to -2.88 mmHg) between higher versus lower doses. Another trial, SUSTAIN 5⁵⁸, showed that semaglutide 0.5 mg did not significantly reduce SBP by 3.30 mmHg (95% CI -6.91 to 0.31), but semaglutide 1 mg showed a significant reduction in SBP by 6.30 mmHg (95% CI -9.92 to -2.68), suggesting a possible dose-dependent effect on SBP reduction between 0.5 mg and 1 mg. Notably, patients with lower baseline SBP had a trend towards more marked SBP reduction than those with higher baseline SBP, with mean SBP reduction 5.19 mmHg (95% CI -7.28 to -3.09) among studies with mean SBP 120-129 mmHg vs studies with mean SBP 130-139 mmHg, which showed mean SBP reduction 2.66 (95% CI -3.84 to -1.48). The effect was driven mainly by 2 RCTs with mean SBP 120-129 mmHg, OASIS 1⁵⁴ and Wilding et al., (2021)⁶³, which had a mean SBP reduction of 6.30 and 5.94 mmHg, respectively.

SBP reduction, Liraglutide

Liraglutide demonstrated a statistically significant, but clinically modest SBP reduction compared to placebo with a MD of -2.61 mmHg. Two large RCTs that recruited > 1,000 participants, such as le Roux et al., 2017⁴⁰ and Pi-Sunyer et al., 2015⁴⁵ were able to successfully demonstrate this modest reduction in SBP. This effect was consistent with the finding of a pooled analysis of 6 RCTs, which enrolled 2,783 patients with type 2 diabetes mellitus, as there was a mean SBP reduction of 2.7 and 2.9 mmHg among patients with liraglutide 1.2 mg and 1.8 mg, respectively.⁸⁶ Another meta-analysis that included 18 RCTs with 7,616 individuals was also consistent with our study's results, as there was mean SBP reduction of 3.18 mmHg with liraglutide treatment (95% CI -4.32 to -2.05) compared to placebo.¹⁴ Unlike semaglutide, treatment duration did not have a significant effect on SBP reduction. This suggests that liraglutide may only need to be given for at least 5 weeks for it to exert a decrease in SBP, as seen in Liakos et al., 2018⁴¹. Varying doses of liraglutide decreased SBP modestly with statistical significance compared to placebo, but their effects were not significantly different compared to each other. This suggests that modest SBP reduction may be attained by using a dose as low as 0.6 mg, as Kuhadiya et al. (2016)³⁵ has shown this statistically significant but clinically modest treatment effect on SBP using this dose, with decrease of SBP by 2.50 mmHg (95% CI -4.97 to -0.03).

A lower baseline SBP showed an impact on SBP reduction by liraglutide, as RCTs with mean baseline SBP 120-129 mmHg showed a statistically significant but clinically modest decrease in SBP of 2.64 (95% CI -3.36 to -1.93), whereas RCTs with mean baseline SBP 130-139 mmHg showed a trend towards, albeit nonsignificant decrease in SBP of 0.98 mmHg (95% CI -3.03 to 1.07). This was in contrast to a correlation analysis of an RCT of liraglutide for

patients with type 2 diabetes, as it showed that higher baseline SBP was associated with a greater SBP reduction with liraglutide treatment; this study attributed the finding to non-systematic measurement errors, in which a single baseline BP measurement varies from the patient's long-term average BP, a phenomenon known as "regression to the mean".⁸⁷ Further studies may need to be conducted to determine the relationship of baseline SBP and SBP reduction on liraglutide.

SBP reduction, Dulaglutide

Dulaglutide modestly reduced SBP with a MD of -1.46 mmHg. This effect was driven by REWIND⁸² and Ferdinand et al., (2014)⁶⁶ trials; however, some RCTs such as AWARD-8⁶⁴ and Miyagawa et al., 2015⁶⁸, did not show statistically significant decrease in SBP. The results of our study were consistent with a meta-analysis of 6 RCTs on dulaglutide, which showed an SBP reduction of 2.6 mmHg (95% CI -3.8 to -1.5) compared to placebo.⁸⁸ Treatment duration of dulaglutide did not significantly alter the magnitude of SBP reduction. Dulaglutide dose was shown to have an effect on SBP reduction. Studies that used dulaglutide dose of less than 1 mg had a trend towards, but nonsignificant, reduction of SBP by 0.84, whereas RCTs that used dulaglutide dose of 1 mg and above had a modest decrease in SBP of 1.90 mmHg (95% CI -2.92 to -0.88). This can be explained by Miyagawa et al., 2015⁶⁸, which utilized a dose of 0.75 mg but had a nonsignificant increase in SBP 0.09 mmHg (95% CI -0.12 to 0.30). These findings are suggestive of a dose-dependent response of dulaglutide and SBP.

SBP reduction, Exenatide

Exenatide modestly reduced SBP with a MD of 3.36 mmHg. Our results were consistent with an earlier meta-analysis by Wang et al. (2013),⁸⁹ which included 7 RCTs that compared exenatide with placebo among 1,334 patients with T2DM, with a statistically significant but

clinically modest SBP reduction of 5.24 mmHg (95% CI -6.88 to -3.59). However, an RCT that used dapagliflozin and exenatide demonstrated no SBP reduction among patients treated with SBP alone, but patients treated with dapagliflozin and empagliflozin had the greatest decrease in SBP of 6.4 mmHg and 6.7 mmHg (after 1.5 and 16 weeks respectively), compared to patients treated with empagliflozin alone, as they had a decrease in SBP of 4.5 mmHg and 1.8 mmHg (after 1.5 and 16 weeks, respectively); these results indicate a synergistic effect on SBP reduction by an SGLT2i and a GLP-1RA with multiple mechanisms such as non-osmotic sodium storage, changes in baroreceptor reflex setpoint or renal sympathetic nerve activity, or a central neural pathway.⁹⁰

Modest SBP reduction was noted among RCTs with longer treatment duration of at least 24 weeks. Our results indicate a duration-dependent effect of exenatide, in which SBP reduction may only occur if administered for at least 24 weeks.

DBP reduction

Of the GLP-RAs included in our meta-analysis, we found that only exenatide reduced DBP with statistical significance, albeit clinically modest with a mean difference of -0.94 mmHg (95% CI, -1.78 to -0.10), p=0.03), driven mainly by the Moretto et al. (2008) and Buse et al. (2011) trials. These findings are supported by previous meta-analyses, which also found a reduction in blood pressure with exenatide only.^{13, 91} However, a meta-analysis by Hu et al. (2020)⁹² found a statistically significant decrease in DBP with GLP-RAs compared to baseline, although it must be noted that this meta-analysis additionally included albiglutide and taspoglutide, which are not included in our study, and also included active comparators such as insulin, sulfonylureas, and DPP-4 inhibitors. Another meta-analysis by Wang et al. (2013)⁸⁹ also

found a statistically significant decrease in DBP with liraglutide in contrast to our study, but also found the same treatment effect of DBP reduction as our study with exenatide.

Our meta-analysis and previous studies demonstrate that systolic BP, not diastolic BP, is the predominant component GLP-1 receptor-mediated BP control, mainly due to its effects on extracellular volume homeostasis.⁹³ Although GLP-1 receptor agonists exert vasodilatory effects through production of NO, GLP-1RAs have also been found to improve arterial stiffness, which may attenuate the BP-lowering effect of GLP-1RAs on diastolic blood pressure.^{94, 95}

Weight loss is a notable effect of GLP-1RAs, as shown in multiple RCTs and metaanalyses^{96, 97} and weight loss decreases SBP by 5 mmHg among patients with hypertension and 2-3 mmHg among patients with normotension, with a dose-response relationship of around 1 mmHg per kg of weight loss.⁹⁸ This effect of weight loss on SBP reduction was demonstrated in our meta-regression analysis, which revealed that mean weight change was associated with modest SBP reduction for RCTs that utilized semaglutide (p=0.02, tau2 3.047, R2 analog=37.65) and dulaglutide (p=0.00, tau2 6.6, R2 analog=100.00). However, it was not demonstrated in studies that used exenatide and liraglutide. The shorter half-lives of these two medications could potentially explain the lack of association, especially that exenatide and liraglutide are administered daily and dulaglutide and subcutaneous semaglutide are administered weekly⁹⁹, but more studies may be needed to further elucidate the effect of weight reduction on SBP reduction. The aforementioned meta-analysis by Hu et al. $(2020)^{92}$, showed that weight loss was associated with net change in SBP and even in placebo-corrected SBP changes. A meta-analysis that included 6 RCTs on dulaglutide demonstrated that SBP reduction was mostly mediated by the weight-independent effects of dulaglutide, as only 36% of SBP reduction was mediated by weight loss⁸⁸, thus indicating that dulaglutide decreases SBP not just through its effect on weight but also through other mechanisms.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.29.24301971; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Our study revealed that mean change in BMI was associated with the treatment effect for SBP reduction for semaglutide only (p=0.00, tau2 0.165, R2 analog=92.57) but not for other GLP-1RAs. Interestingly, while weight loss was associated with SBP reduction for dulaglutide, it was not consistent with BMI reduction as there was no association with SBP reduction, even though weight is a component of BMI. This could be explained by the fact that BMI (expressed in kg/m2) is also determined by height, and that BMI is inversely proportional to the square of height.¹⁰⁵ The effect of height could possibly blunt the effect of BMI on SBP reduction, hence the lack of association with dulaglutide, but more studies may need to be done to determine the effect of BMI on SBP reduction.

Meta-regression analysis revealed that mean change in A1C was associated with the treatment effect for SBP reduction for semaglutide (p=0.010, tau2 2.989, R2 analog=28.27), exenatide (p=0.03, tau2 9.8, R2 analog=80.20), and dulaglutide (p=0.002, tau2 0.1308, R2 analog=81.80), but not for liraglutide. The previously mentioned meta-analysis by Hu et al. $(2020)^{92}$ showed that HbA1c change was associated with net change in SBP and even in placebo-corrected SBP changes. However, after performing adjustment for weight change, the association between A1C reduction and SBP reduction became insignificant; this suggests that the effect of A1C reduction on BP changes may depend on weight reduction, considering that glycemic control can be achieved better with weight loss.⁹²

Strength and limitations

To our knowledge, this is the first meta-analysis and meta-regression to comprehensively report on the efficacy of GLP-1RAs in reducing blood pressure. There are several limitations that are important to note. This is a study-level meta-analysis, and we could not access individual patient data. Additional limitations include heterogeneity in GLP-1RA studies. Publication bias may

also be present, the extent of which could not fully be quantified. However, every effort possible was made to limit bias by utilizing a robust analytical approach to adjust for potential moderators through subgroup analyses and regression analysis.

Conclusions

GLP-1RAs reduced SBP from 1.46 to 3.40 mmHg. DBP reduction from GLP-RAs was very minimal to none. Mean changes in weight, BMI and A1c directly drive the reduction in SBP. SBP reduction for semaglutide was more marked for patients on prolonged therapy, those with lower baseline mean SBP and for patients without DM. SBP reduction of liraglutide and dulaglutide were more pronounced among patients with a lower baseline mean SBP. Only exenatide reduced DBP with statistical significance, albeit the treatment effect was clinically modest. Further study is needed to elucidate the potential mechanisms of this blood pressure effects from GLP-1RA.

Perspectives

GLP-1RAs, including semaglutide, liraglutide, exenatide, and dulaglutide, exhibit statistically significant but clinically modest efficacy in reducing SBP independently of glycemic control. Semaglutide leads with the greatest SBP reduction, influenced by factors such as weight, baseline SBP, and diabetes status. Liraglutide and dulaglutide also effectively lower SBP, while exenatide additionally impacts DBP. These findings suggest that GLP-1RAs present a promising approach for cardiovascular health management, warranting further investigation into their precise mechanisms. Their weight-independent effects, potential for personalized therapy, and emerging mechanistic insights pave the way for broader application in diverse patient populations, ultimately improving cardiovascular health across a wider range.

Novelty and relevance

What is new?

• SBP reduction from the use of GLP-1RAs is significant, independent of its effects on glycemia.

- Semaglutide demonstrated superior SBP lowering with greater change in HbA1c and body mass index compared placebo but with less SBP lowering among patients with diabetes.
- DBP reduction was not observed among the GLP-1RA with the exception of a marginal decrease in DBP in patients taking exenatide.

What is relevant?

The class of GLP-1RA provide modest improvement in systolic blood pressure and may serve as a useful strategy for patients with overweight/obesity and hypertension.

Clinical/Pathophysiological implications?

- Mechanisms resulting in the BP lowering effect remain unknown, and the clinical benefit resulting from BP reduction specifically from GLP-1RA require further investigation.
- Future research directions encompass investigating GLP-1RA-induced SBP reduction mechanisms through mechanistic studies, gene expression analysis, and advanced imaging; examining the impact of patient characteristics on response and conducting trials targeting specific subpopulations; assessing long-term effects and clinical outcomes through observational studies and RCTs; exploring novel GLP-1RA formulations and targets, including extended half-lives and additional receptors; and leveraging emerging technologies for personalized treatment strategies by integrating data from diverse sources.
- Addressing these areas promises a deeper understanding of GLP-1RAs in blood pressure control, enhancing cardiovascular outcomes in T2DM and associated conditions

Statement of Ethics: Ethics approval for this paper is not required because this study is based exclusively on published literature. Patient consent was not needed as this study was based on publicly available data.

Conflict of Interest: The authors declare that they have no conflicts of interest relevant to the content of this manuscript.

Funding: No specific financial support was obtained to prepare this article.

Author Contributions: Frederick B. Rivera MD: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Validation; Writing - original draft; Writing - review & editing; John Paul Aparece, MD, Grace Nooriza O. Lumbang, MD;Danielle Rose Magno Gaid, MD, Linnaeus Louisse A. Cruz, MD: Writing – Data curation; review & editing; Grace Nooriza O. Lumbang, MD;Danielle Rose Magno Gaid, MD, Frederick B. Rivera MD and Linnaeus Louisse A. Cruz, MD: Data Curation; Writing - original draft; Writing - review & editing; John Vincent Magalong, MD: Writing - original draft; Writing - review & editing; John Vincent Magalong, MD and Nathan Ross B. Bantayan, BSc: Data curation; Data

interpretation; Formal analysis; Writing - original draft; Writing - review & editing; Frederick

B. Rivera, MD: Writing - original draft; Writing - review & editing; Kyla M. Lara-Breitinger,

MD; Martha Gulati, MD MS; George Bakris, MD: Writing - review & editing.

Data Availability Statement: All data generated or analyzed during this study are included in

this article. Further inquiries can be directed to the corresponding author.

Reference:

1. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-s57.

2. Fu EL, Clase CM, Janse RJ, Lindholm B, Dekker FW, Jardine MJ, Carrero JJ. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. Int J Cardiol. 2022;352:172-9.

3. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-84.

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.

5. Michos ED, Lopez-Jimenez F, Gulati M. Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. J Am Heart Assoc. 2023;12(11):e029282.

6. Winquist RJ, Gribkoff VK. Cardiovascular effects of GLP-1 receptor agonism. Adv Pharmacol. 2022;94:213-54.

7. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136(9):849-70.

8. Helmstädter J, Keppeler K, Küster L, Münzel T, Daiber A, Steven S. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor. Br J Pharmacol. 2022;179(4):659-76.

9. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390-403.

10. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157(8):1340-51.

11. Ribeiro-Silva JC, Tavares CAM, Girardi ACC. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. Curr Opin Pharmacol. 2023;69:102355.

12. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1).

13. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26-37.

14. Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a metaanalysis of liraglutide randomized controlled trials. BMC Endocr Disord. 2019;19(1):4.

15. Wu W, Tong HM, Li YS, Cui J. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine. 2023.

16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.

18. Goldkuhle M, Guyatt GH, Kreuzberger N, Akl EA, Dahm P, van Dalen EC, et al. GRADE concept 4: rating the certainty of evidence when study interventions or comparators differ from PICO targets. J Clin Epidemiol. 2023;159:40-8.

19. Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103-10.

20. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69-77.

21. Loganathan J, Cohen AC, Kaloupis GM, Harris C, Chronopoulos A, James V, et al. A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study). J Diabetes Complications. 2022;36(5):108188.

22. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221-32.

23. Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU, Nørgaard K. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulinpump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial. Diabetes Obes Metab. 2020;22(4):492-500.

24. de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia. 2014;57(9):1812-9.

25. Mok J, Adeleke MO, Brown A, Magee CG, Firman C, Makahamadze C, et al. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial. JAMA Surg. 2023;158(10):1003-11.

26. Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahrén B, Torffvit O, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015;351:h5364.

27. Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3(11):e003995.

28. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-16.

29. Bojer AS, Sørensen MH, Bjerre J, Gaede P, Vejlstrup N, Madsen PL. Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021;23(10):2374-84.

30. Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015;170(5):845-54.

31. Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol. 2015;14:41.

32. Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22(10):1742-52.

33. Idorn T, Knop FK, Jørgensen MB, Jensen T, Resuli M, Hansen PM, et al. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016;39(2):206-13.

34. Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36(10):3276-82.

35. Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, Batra M, et al. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. Diabetes Care. 2016;39(6):1027-35.

36. Kumarathurai P, Anholm C, Nielsen OW, Kristiansen OP, Mølvig J, Madsbad S, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Cardiovasc Diabetol. 2016;15(1):105.

37. Kumarathurai P, Anholm C, Fabricius-Bjerre A, Nielsen OW, Kristiansen O, Madsbad S, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. J Hypertens. 2017;35(5):1070-8.

38. Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovasc Diabetol. 2021;20(1):12.

39. Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(7):719-28.

40. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409.

41. Liakos A, Lambadiari V, Bargiota A, Kitsios K, Avramidis I, Kotsa K, et al. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2019;21(3):517-24.

42. Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-30.

43. Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84-94.

44. Mensberg P, Nyby S, Jørgensen PG, Storgaard H, Jensen MT, Sivertsen J, et al. Nearnormalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):172-80.

45. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.

46. Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41.

47. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017;176(1):77-86.

48. Wadden TA, Walsh OA, Berkowitz RI, Chao AM, Alamuddin N, Gruber K, et al. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. Obesity (Silver Spring). 2019;27(1):75-86.

49. Whicher CA, Price HC, Phiri P, Rathod S, Barnard-Kelly K, Ngianga K, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized double blind placebo controlled trial. Diabates Obes Metab. 2021;22(6):1262.71

randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021;23(6):1262-71. 50. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206.

51. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-84.

52. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-25.

53. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Twoyear effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-91.

54. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-19.

55. Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515-27.

56. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51.

57. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-60.

58. Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291-301.

59. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017;318(15):1460-70.

60. Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR. A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in

Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. Diabetes Care. 2018;41(9):1926-37.

61. O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-49.

62. Gullaksen S, Vernstrøm L, Sørensen SS, Ringgaard S, Laustsen C, Funck KL, et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia. 2023;66(5):813-25.

63. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.

64. Dungan KM, Weitgasser R, Perez Manghi F, Pintilei E, Fahrbach JL, Jiang HH, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475-82.

65. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30.

66. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731-7.

67. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10):1260-7.

68. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17(10):974-83.

69. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, Glass LC. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):468.e9-17.

70. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-12.

71. Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012;35(1):4-11.

72. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.

73. Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen A, Zeeman VA, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19).

74. Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12(12):1058-65.

75. Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained

reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017;19(9):1276-88.

76. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448-60.

77. Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes Obes Metab. 2018;20(7):1602-14.

78. Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, investigators D-N-s. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19(7):979-88.

79. Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050-5.

80. Rosenstock J, Buse JB, Azeem R, Prabhakar P, Kjems L, Huang H, Baron MA. Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. Diabetes Care. 2018;41(2):333-40.

81. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-99.

82. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131-8.

83. Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52(3):516-26.

84. Kannapiran M, Nisha D, Madhusudhana Rao A. Underestimation of impaired kidney function with serum creatinine. Indian J Clin Biochem. 2010;25(4):380-4.

85. Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(3).

86. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399-405.

87. Wijkman MO, Dena M, Dahlqvist S, Sofizadeh S, Hirsch I, Tuomilehto J, et al. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2019;21(1):105-15.

88. Ferdinand KC, Dunn J, Nicolay C, Sam F, Blue EK, Wang H. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):49.

89. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737-49.

90. van Ruiten CC, Śmits MM, Kok MD, Serné EH, van Raalte DH, Kramer MHH, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and

their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21(1):63.

91. Sun F, Wu S, Chai S, Yang Z, Yu K, Zhan S. Impact of Glp-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Value Health. 2014;17(7):A719-20.

92. Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. J Am Heart Assoc. 2020;9(7):e015323.

93. Martins FL, Bailey MA, Girardi ACC. Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control: Role of Proximal Tubule Na. Hypertension. 2020;76(3):839-48.

94. Lundgren JR, Færch K, Witte DR, Jonsson AE, Pedersen O, Hansen T, et al. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovasc Diabetol. 2019;18(1):130.

95. Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, et al. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8.

96. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011(10):CD006423.

97. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.

98. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart

Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. 99. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.

Table 1: Characteristics of included studies	

Author (year) / Name of Trial	Phase	Population	No. of patients	Age, years (mean)	Female, n (%)	Drug (dose and frequency)	Comparator	Duration of treatment (weeks)	Primary endpoint
Jorsal et al. (2016) / LIVE Trial ²⁰	Phase 2	Patients with or without diabetes who had CHF, an LVEF ≤45% and NYHA functional class I–III	241	65	26 (10.8)	Liraglutide (1.8 mg OD)	Placebo	24 weeks	Change in LVEF
Loganathan et al. (2022) / ELAID Trial ²¹	Phase 4	Patients with T2DM and without concurrent antiplatelet therapy	16	60	6 (37.5)	Liraglutide (1.8 mg OD)	Placebo	26 weeks	Change in maximum slope of platelet aggregation
Kadowaki et al (2022) / STEP 6 Trial ⁵¹	Phase 3	Adults with at least one self- reported unsuccessful dietary attempt to lose body weight	401	51	148 (36.9)	Semaglutide (2.4 mg and 1.7 mg QW)	Placebo	68 weeks	Change in BW and proportion of subjects achieving at least 5% reduction of baseline BW
Davies et al. (2021) / STEP 2 Trial ⁵²	Phase 3	Adults with T2DM and with at least one unsuccessful dietary effort to lose weight	807	55	413 (51.2)	Semaglutide (2.4 mg QW)	Placebo	68 weeks	Percentage change in BW from baseline and loss of at least 5% of baseline BW
Gadde et al. (2017) / DURATION- NEO-2 Trial ⁷⁸	Phase 3	Adults with T2DM on a stable regimen of metformin	364	54	172 (47.3)	Exenatide (2.0 mg QW)	Sitagliptin or Placebo	28 weeks	Change in HbA1c
Knop et al. (2023) / OASIS 1 Trial ⁵⁵	Phase 3	Obese adults with at least one self-reported dietary weight loss effort	667	50	485 (72.7)	Semaglutide (50 mg OD)	Placebo	68 weeks	Percentage change in BW and whether participants reached at least 5% BW reduction

Siskind et al. (2017) / CODEX Trial ⁷⁹	Phase 2	Adults with a clinical diagnosis of schizophrenia or schizoaffective disorder taking oral clozapine	28	-	10 (35.7)	Exenatide (2 mg QW)	Usual care (Clozapine alone)	24 weeks	Difference in the proportion of participants with >5% BW reduction
Moretto et al. (2008) ⁷⁶	Phase 2	Overweight or obese adults with T2DM	232	54	102 (44.0)	Exenatide (5 ug or 10 ug BID)	Placebo	24 weeks	Change in HbA1c
Lingvay et al. (2018) ⁶⁰	Phase 2	Adults with T2DM and on stable diabetes treatment	705	57	326 (46.2)	Semaglutide (0.05, 0.1, 0.2 or 0.3 mg OD)	Liraglutide or Placebo	26 weeks	Change in HbA1c
Dungan et al. (2016) / AWARD-8 Trial ⁶⁴	Phase 3	Adults with a BMI of \leq 45 kg/m2 with T2DM not optimally controlled with diet and exercise	300	58	167 (55.7)	Dulaglutide (1.5 mg QW)	Placebo	24 weeks	Change in HbA1c
Dejgaard et al. (2019) / Lira Pump Trial ²³	Phase 3	Adults with T1DM, treated with CSII, in non-optimal glycemic control	44	50	30 (68.2)	Liraglutide (1.8 mg OD)	Placebo	26 weeks	Change in HbA1c
Gerstein et al. (2019) / REWIND Trial ⁶⁵	Phase 3	Adults with T2DM whose HbA1c was 9.5% or less, on stable doses of up to two oral glucose-lowering drugs	9,901	66	4,589 (46.3)	Dulaglutide (1.5 mg QW)	Placebo	Treatment period is not uniform for all subjects	MACE
O'Neil et al. (2018) ⁶¹	Phase 2	Obese adults without diabetes	957	47	619 (64.7)	Semaglutide (0.05, 0.1, 0.2, 0.3 or 0.4 mg OD) or Liraglutide (3 mg OD)	Placebo and active control (Liraglutide)	52 weeks	Percentage weight loss
Lundkvist et al. (2017) ⁷⁵	Phase 2a	Obese adults without diabetes	50	53	30 (60.0)	Exenatide (2 mg QW)	Placebo	52 weeks	Change and percent change in BW

Mosenzon et al. (2019) / PIONEER 5 Trial ⁵⁶	Phase 3a	Adults with T2DM and an eGFR of 30–59 mL/min per 1.73 m2	324	70	168 (51.9)	Semaglutide (14 mg OD)	Placebo	26 weeks	Change in HbA1c
Wilding et al. (2021) ⁶³	Phase 3	Adults with one or more self-reported unsuccessful dietary efforts to lose weight	1,961	46	1,453 (74.1)	Semaglutide (2.4 mg QW)	Placebo	68 weeks	Percentage change in BW and weight reduction of at least 5%
Lincoff et al. (2023) / SELECT Trial ⁴	Phase 4	Overweight or obese patients who had preexisting cardiovascular disease but had no history of diabetes	17,604	62	12,732 (72.3)	Semaglutide (2.4 mg QW)	Placebo	136 weeks	Composite of death from cardiovascular causes, nonfatal myocardial infarction, or non- fatal stroke
Husain et al. (2019) / PIONEER 6 Trial ⁵⁷	Phase 3	Patients with established cardiovascular disease or chronic kidney disease	3,183	66	1,007 (31.6)	Semaglutide (14 mg OD)	Placebo	69 weeks	MACE
Gill et al. (2010) ⁷²	Phase 2	Adults on a stable metformin dose for 30 days or on TZD for 120 days	54	57	24 (44.4)	Exenatide (10 µg BID)	Placebo	12 weeks	Change in mean 24-hour HR
Ghanim et. al (2020) ³²	Phase 3	Overweight or obese adults with T1DM, on stable basal and bolus insulin, and had no detectable C-peptide in plasma	84	47	60 (71.4)	Liraglutide (1.8 mg OD)	Placebo	26 weeks	Change in HbA1c
Sorli et al. (2017) / SUSTAIN 1 Trial ⁵⁸	Phase 3a	Adults with T2DM treated with only diet and exercise alone	387	54	177 (45.7)	Semaglutide (0.5 mg or 1.0 mg QW)	Placebo	30 weeks	Change in HbA1c

le Roux et al. (2017) ⁴⁰	Phase 3a	Obese adults with stable bodyweight, with dyslipidemia or hypertension, or both	2,254	48	1,714 (76.0)	Liraglutide (3.0 mg OD)	Placebo	160 weeks	Proportion of individuals with type 2 diabetes at 160 weeks
Davies et al. (2017) ⁵⁰	Phase 2	Adults with T2DM and insufficient glycemic control	632	57	395 (62.5)	Semaglutide (2.5, 5, 10, 20, and 40 mg OD)	Placebo or SC Semaglutide	26 weeks	Change in HbA1c
Smits et al. (2017) ⁴⁷	Phase 3	Patients with T2DM	36	61	9 (25.0)	Liraglutide (1.8 mg OD)	Placebo	12 weeks	Change in LF/HF ratio
Idorn et al. (2016) ³³	Phase 2	Adults with T2DM and ESRD	23	66	8 (34.8)	Liraglutide (0.6 mg OD)	Placebo	12 weeks	Dose-corrected trough concentration of liraglutide in plasma at the final trial visit
Rubino et al. (2021) / STEP 4 Trial ⁵³	Phase 3a	Adults with at least one self- reported unsuccessful dietary effort to lose weight	803	46	634 (79.0)	Semaglutide (2.4 mg QW)	Placebo	68 weeks	Percent change in BW
Grunberger et al. (2012) ⁶⁷	Phase 2	Adults with T2DM who were anti-hyperglycemic medication-naïve or had discontinued metformin monotherapy	167	57	90 (54.9)	Dulaglutide (0.1, 0.5, 1.0 or 1.5 mg QW)	Placebo	12 weeks	Change in HbA1c
Kim et al. (2013) ³⁴	Phase 3	Adults with prediabetes	51	58	33 (64.7)	Liraglutide (1.8 mg OD)	Placebo	14 weeks	Percentage loss of baseline BW and change in insulin resistance
Kumarathurai et al. (2017) ³⁷	Phase 3	Overweight patients with T2DM and stable CAD	24	63	22 (91.7)	Liraglutide (1.8 mg OD)	Placebo	12 weeks	Change in mean 24-hour SBP and DBP

Kosiborod et al (2023) / STEP HFpEF trial ³		Adults with LVEF >/= 45%; BMI >/= 30; NYHA class II, III, or IV symptoms; KCCQ-CSS score < 90 points; 6MWT >/= 100 m; and at least 1 of the following: elevated LV filling pressures, elevated natriuretic peptide levels plus echocardiographic abnormalities, or hospitalization for HF in the 12 months before screening plus ongoing treatment with diuretics or echocardiographic abnormalities	529	69	297 (56.1)	Semaglutide (2.4 mg QW)	Placebo	52 weeks	Change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ- CSS)
Ferdinand et al. (2014) ⁶⁶	Phase 3	Patients with T2DM, on ≥1 oral antihyperglycemic medication for ≥1 month	755	57	363 (48.1)	Dulaglutide (1.5mg or 0.75mg QW)	Placebo	26 weeks	Change in mean 24-hour SBP
Kumarathurai et al. (2016) ³⁶	Phase 2	Adults with T2DM and stable CAD	41	62	9 (22.0)	Liraglutide (1.8 mg BID)	Placebo	24 weeks	Change in LVEF
Faber et al. (2015) ³¹		Adults with T2DM on monotherapy with metformin or SU or a combination	20	57	5 (25.0)	Liraglutide (1.2 mg OD)	Usual diabetic therapy (Metformin or SU or combination)	10 weeks	Effect on coronary microcirculation, estimated by CFR
Buse et al. (2011) ⁷⁰	Phase 2	Adults with T2DM, receiving insulin glargine at a minimum of 20 U/day	259	59	111 (42.9)	Exenatide (10 µg BID)	Placebo	30 weeks	Change in HbA1c

Chen et al. (2015) ⁸³	Phase 3	Patients with NSTEMI	90	58	24 (26.7)	Liraglutide (1.8 mg OD)	Placebo	1 week	Change in LVEF
Kumarathurai et al. (2021) ³⁸	Phase 2	Overweight patients with stable CAD, LVEF >40% and T2DM	30	63	6 (20.0)	Liraglutide (1.8 mg OD)	Placebo	24 weeks	Change in diastolic function parameters
Whicher et al (2021) ⁴⁹	Phase 2	Adults with schizophrenia, schizoaffective or first- episode psychosis who are overweight or obese	47	43	13 (27.7)	Liraglutide (3 mg OD)	Placebo	24 weeks	Estimate of adherence to investigational product
Davies et al. (2015) / SCALE Diabetes Trial ⁸¹	Phase 3	Adults with T2DM treated with diet and exercise alone or in combination with 1 to 3 oral hypoglycemic agents	827	55	421 (50.9)	Liraglutide (3.0 mg or 1.8 mg OD)	Placebo	56 weeks	Relative change in BW, proportion of participants losing 5% or more of BW, and proportion losing more than 10% of BW
Kuhadiya et al. (2016) ³⁵	Phase 4	Adults with T1DM, with fasting C-peptide < 0.1 nmol/L	63	43	35 (55.6)	Liraglutide (0.6 mg, 1.2 mg or 1.6 mg OD)	Placebo	12 weeks	Change in mean weekly BG concentrations
de Wit et al. (2014) / ELEGANT Trial ²⁴	Phase 2	Adults with T2DM who had documented weight gain of ≥4% body weight since initiation of insulin treatment.	50	57	19 (38.0)	Liraglutide (1.8 mg OD)	Placebo	26 weeks	Change in BW
Klausen et al. (2022) ⁷³	Phase 2	AUD patients who had a minimum of 5 heavy drinking days in the past 30 days	127	52	51 (40.2)	Exenatide (2 mg QW)	Placebo	26 weeks	Reduction in number of heavy drinking days.

Mensberg et al. (2016) ⁴⁴	Phase 2	Adults with T2DM treated with diet and/or metformin and sedentary lifestyle	33	57	10 (30.3)	Liraglutide (1.8 mg OD)	Placebo	16 weeks	Change in HbA1c
Miyagawa et al. (2015) ⁶⁸	Phase 3	Adults who were OAM- naïve or had discontinued OAM monotherapy	492	57	91 (18.5)	Liraglutide (0.9 mg OD)	Placebo or Dulaglutide	26 weeks	Change in HbA1c
Lundgren et al. (2021) ⁴²	Phase 3	Obese adults	195	43	124 (63.6)	Liraglutide (3 mg OD)	Placebo	48 weeks	Change in BW
Guja et al. (2017) / DURATION-7 Trial ⁷⁷	Phase 3	Adults with T2DM, on an insulin regimen in combination with diet and exercise or with metformin	461	58	240 (52.1)	Exenatide (2 mg QW)	Placebo	28 weeks	Change in HbA1c
Matikainen et al. (2018) ⁴³	Phase 2	Obese patients with T2DM, under treatment with lifestyle changes or metformin	22	62	6 (27.3)	Liraglutide (1.8 mg OD)	Placebo	16 weeks	Changes in weight, HbA1c, β-hydroxybutyrate and SBP
Liakos et al. (2018) ⁴¹	Phase 2	Adult patients with inadequately controlled T2DM despite stable antihyperglycemic therapy	62	61	21 (33.9)	Liraglutide (1.2 mg OD)	Placebo	5 weeks	Change in 24-hour ambulatory SBP
Pi-Sunyer et al. (2015) ⁴⁵	Phase 3	Obese adults who had stable body weight	3,731	45	2,928 (78.5)	Liraglutide (3 mg OD)	Placebo	56 weeks	Weight change, the proportion of patients who lost at least 5%, and those who lost more than 10% of their baseline BW
Larsen et al. (2017) ³⁹	Phase 2	Overweight or obese adults with a schizophrenia spectrum disorder who were receiving clozapine or olanzapine and had prediabetes	103	42	37 (38.1)	Liraglutide (1.8 mg OD)	Placebo	16 weeks	Change in glucose tolerance

Liutkus et al. (2010) ⁷⁴	Phase 3	Adults with T2DM, with suboptimal glycemic control while taking stable doses of TZD therapy or combined metformin and TZD therapy	165	55	67 (40.6)	Exenatide (10 mcg BID)	Placebo	26 weeks	Change in HbA1c
Bojer et al. (2021) ²⁹	Phase 3	Adults with T2DM with signs of diastolic dysfunction	40	62	8 (20.0)	Liraglutide (1.8 mg OD)	Placebo	18 weeks	Change in left ventricle ePFR and left atrium PEF
Sandsdal et al. (2023) ⁴⁶	Phase 3	Obese adults	195	43	124 (63.6)	Liraglutide (3 mg OD)	Placebo or Exercise	52 weeks	Change in MetS-Z, abdominal obesity, and CRP
Wadden et al. (2019) ⁴⁸	Phase 2	Obese adults with prior lifetime weight loss effort with diet and exercise	150	48	119 (79.3)	Liraglutide (3 mg OD)	Behavioral Therapy	52 weeks	Change in BW
Garvey et al (2022) / STEP 5 Trial ⁵⁴	Phase 3	Obese adults with at least one self-reported unsuccessful dietary effort to lose body weight	304	47	236 (77.6)	Semaglutide (2.4 mg QW)	Placebo	104 weeks	Percentage change in BW and achievement of weight loss of at least 5%
Rosenstock et al. (2018) / FREEDOM-1 Trial ⁸⁰	Phase 3	Adults with T2DM receiving stable treatment with diet and exercise alone or with metformin, SUs, or pioglitazone	460	56	188 (40.9)	Exenatide (40 μg or 60 μg OD)	Placebo	39 weeks	Change in HbA1c
Mok et al. (2023) / BARI- OPTIMISE Trial ²⁵	Phase 3a	Patients with poor weight loss after metabolic surgery and a suboptimal nutrient- stimulated GLP-1 response	70	46	52 (74.3)	Liraglutide (3.0 mg OD)	Placebo	24 weeks	Percentage change in BW
Rodbard et al. (2018) / SUSTAIN 5	Phase 2	Adults with T2DM receiving stable basal insulin therapy alone or in	396	47	174 (43.9)	Semaglutide (0.5 mg or 1.0 mg QW)	Placebo	30 weeks	Change in HbA1c

Trial ⁵⁹		combination with metformin							
Lind et al. (2015) / MDI Liraglutide trial ²⁶	Phase 3a	Overweight or obese adults with T2DM treated with multiple daily insulin injections	124	59	44 (35.5)	Liraglutide (1.8 mg OD)	Placebo	24 weeks	Change in HbA1c
Gullaksen et al. (2023) ⁶²	Phase 3	Patients with T2DM, with established CVD, heart failure or CKD	80	64	19 (23.8)	Semaglutide (1.0 mg QW)	Placebo or Empagliflozin	16 weeks	Improvement in kidney tissue oxygenation
Dushay et al. (2012) ⁷¹	Phase 3	Overweight or obese adult women without diabetes	41	70	41 (100.0)	Exenatide (10 ug BID)	Placebo	16 weeks	Change in body weight and BMI
Astrup et al. (2009) ²⁸	Phase 3	Obese adults	564	48	429 (76.1)	Liraglutide (1.2 mg, 1.8 mg, 2.4 mg or 3 mg OD)	Placebo or Orlistat	20 weeks	Change in BW
Armstrong et al. (2006) / LEAN Trial ²⁷	Phase 3	Overweight patients who have clinical evidence of non-alcoholic steatohepatitis	52	46	31 (59.6)	Liraglutide (1.8 mg OD)	Placebo	48 weeks	Number of patients with paired liver biopsies and patients with resolution of non-alcoholic steatohepatitis
Apovian et al. (2010) ⁶⁹	Phase 2	Overweight or obese adults with T2DM on a stable dose of metformin or SU, and with a history of stable body weight	194	50	121 (62.4)	Exenatide (10 ug BID)	Placebo and Lifestyle Modifications	24 weeks	Change in BW

Abbreviations: AUD=alcohol use disorder; BG=blood glucose; BID=twice a day; BMI=body mass index; BW=body weight; CAD=coronary artery disease; CFR=coronary flow reserve; CHF=congestive heart failure; CKD=chronic kidney disease; CRP=C-reactive protein; CSII=continuous subcutaneous insulin infusion; CVD=cardiovascular disease; DBP=diastolic blood pressure; ePFR=early peak filling rate; ESRD=end stage renal disease; HR=heart rate; LF/HF=low frequency to high frequency; LVEF=left ventricular ejection fraction; MACE=major adverse cardiovascular events; NSTEMI=non-ST elevation myocardial infarction; OAM=oral antihyperglycemic medication; OD=once a day; PEF=passive emptying fraction; QW=once a week; SBP=systolic blood pressure; SC=subcutaneous; SU=sulfonylurea; T1DM=type 1 diabetes mellitus; T2DM=type 2 diabetes mellitus; TZD=thiazolidinedione

Study		with 95% CI	(%)
Oral			
M Davies et al. (2017) A	_ _	-2.70 [-7.05, 1.65]	2.11
M Husain et al. (2019) / PIONEER 6	— 1	-3.00 [-4.25, -1.75]	4.67
M Davies et al. (2017) F		-3.00 [-7.63, 1.63]	1.95
M Davies et al. (2017) E	_ _	-3.40 [-8.00, 1.20]	1.97
M Davies et al. (2017) D		-3.50 [-8.10, 1.10]	1.97
M Davies et al. (2017) B		-3.90 [-8.28, 0.48]	2.09
M Davies et al. (2017) C		-5.10 [-9.48, -0.72]	2.09
F. Knop et al. / 2023 (OASIS 1)	-	-6.30 [-8.16, -4.44]	4.12
O Mosenzon et al. (2019) / (PIONEER 5)		-7.00 [-20.85, 6.85]	0.33
Heterogeneity: τ ² = 0.44, l ² = 14.64%, H ² = 1.17	•	-4.06 [-5.19, -2.93]	
Test of $\theta_i = \theta_i$: Q(8) = 9.37, p = 0.31			
Test of $\theta = 0$: z = -7.05, p = 0.00			
Subcutaneously			
l Lingvay et al. (2018) A		0.02 [-0.56, 0.60]	5.11
l Lingvay et al. (2018) B		-0.28 [-0.87, 0.31]	5.10
l Lingvay et al. (2018) C		-0.58 [-1.14, -0.02]	5.11
l Lingvay et al. (2018) D		-0.78 [-1.36, -0.20]	5.11
C Sorli et al. (2017)/ SUSTAIN 1 A		-0.86 [-3.39, 1.67]	3.49
C Sorli et al. (2017)/ SUSTAIN 1 B		-1.02 [-3.53, 1.49]	3.50
Garvey et al. (2022) /(STEP 5 Trial)	- 	-2.40 [-5.46, 0.66]	3.02
P M O'Neil et al. (2018) A		-2.88 [-5.99, 0.23]	2.98
Kosiborod et al. (2023) / (STEP HFpEF trial)	- -	-2.90 [-7.07, 1.27]	2.21
H. Rodbard et al. (2018) / (SUSTAIN 5) A		-3.30 [-6.91, 0.31]	2.59
Gullaksen et al. (2023)		-3.30 [-11.98, 5.38]	0.76
A. M. Lincoff (2023) /SELECT Trial		-3.31 [-3.75, -2.87]	5.16
P M O'Neil et al. (2018) B		-4.18 [-7.27, -1.09]	2.99
P M O'Neil et al. (2018) E		-4.23 [-7.30, -1.16]	3.01
P M O'Neil et al. (2018) F		-4.49 [-7.59, -1.39]	2.98
P M O'Neil et al. (2018) C		-4.68 [-7.78, -1.58]	2.99
M. Davies et al. / 2021 (STEP 2)		-4.80 [-6.59, -3.01]	4.18
P M O'Neil et al. (2018) D		-4.83 [-7.93, -1.73]	2.99
T. Kadowaki et al. / 2022 (STEP 6) A		-5.92 [-8.87, -2.97]	3.11
Wilding et al. (2021)	-	-5.94 [-7.92, -3.96]	4.00
T. Kadowaki et al. / 2022 (STEP 6) B		-6.28 [-9.69, -2.87]	2.73
H. Rodbard et al. (2018) / (SUSTAIN 5) B		-6.30 [-9.92, -2.68]	2.58
P M O'Neil et al. (2018) G		-8.68 [-11.75, -5.61]	3.01
Heterogeneity: $\tau^2 = 3.21$, $I^2 = 90.00\%$, $H^2 = 10.00$	♦ 1	-3.22 [-4.13, -2.31]	
Test of $\theta_i = \theta_i$: Q(22) = 220.01, p = 0.00	Ť	-	
Test of $\theta = 0$: z = -6.94, p = 0.00			
Overall	<u>ا</u>	-3.40 [-4.22, -2.59]	
Heterogeneity: τ^2 = 3.31, I ² = 87.78%, H ² = 8.18			
Test of $\theta_i = \theta_j$: Q(31) = 253.59, p = 0.00			
Test of $\theta = 0$: z = -8.17, p = 0.00			
Test of group differences: $Q_b(1) = 1.30$, p = 0.25		_	

medRxiv preprint doi: https://doi.org/10.1101/2024.01.29.24301971; this version posted January 30, 2024. The copyright holder for this preprint

Study	with 95% Cl	(%)
26 weeks or less		(79)
Lingvay et al. (2018) A	0.02 [-0.56, 0.60]	5.11
Lingvay et al. (2018) B	-0.28 [-0.87, 0.31]	5.10
Lingvay et al. (2018) C	-0.58 [-1.14, -0.02]	5.11
Lingvay et al. (2018) D	-0.78 [-1.36, -0.20]	5.11
M Davies et al. (2017) A	-2.70 [-7.05, 1.65]	2.11
M Davies et al. (2017) F –	-3.00 [-7.63, 1.63]	1.95
Gullaksen et al. (2023)	-3.30 [-11.98. 5.38]	0.76
M Davies et al. (2017) E	-3.40 [-8.00, 1.20]	1.97
M Davies et al. (2017) D	-3.50 [-8.10, 1.10]	1.97
M Davies et al. (2017) B	-3.90 [-8.28. 0.48]	2.09
M Davies et al. (2017) C	-5.10 [-9.480.72]	2.09
O Mosenzon et al. (2019) / (PIONEER 5)	-7.00 [-20.85, 6.85]	0.33
Heterogeneity: $\tau^2 = 0.18$, $I^2 = 37.77\%$, $H^2 = 1.61$	-0.65 [-1.13, -0.16]	
Test of $\theta_{1} = \theta_{1}$; $Q(11) = 17.68$, $p = 0.09$		
Test of $\theta = 0$: $z = -2.58$, $p = 0.01$		
>26 weeks		
C Sorli et al. (2017)/ SUSTAIN 1 A	-0.86 [-3.39, 1.67]	3.49
C Sorli et al. (2017)/ SUSTAIN 1 B	-1.02 [-3.53, 1.49]	3.50
Garvev et al. (2022) /(STEP 5 Trial)	-2.40 [-5.46. 0.66]	3.02
P M O'Neil et al. (2018) A	-2.88 [-5.99, 0.23]	2.98
Kosiborod et al. (2023) / (STEP HFpEF trial)	-2.90 [-7.07, 1.27]	2.21
M Husain et al. (2019) / PIONEER 6	-3.00 [-4.25, -1.75]	4.67
H. Rodbard et al. (2018) / (SUSTAIN 5) A	-3.30 [-6.91, 0.31]	2.59
A. M. Lincoff (2023) /SELECT Trial	-3.31 [-3.75, -2.87]	5.16
P M O'Neil et al. (2018) B	-4.18 [-7.27, -1.09]	2.99
P M O'Neil et al. (2018) E	-4.23 [-7.30, -1.16]	3.01
P M O'Neil et al. (2018) F	-4.49 [-7.59, -1.39]	2.98
P M O'Neil et al. (2018) C	-4.68 [-7.78, -1.58]	2.99
M. Davies et al. / 2021 (STEP 2)	-4.80 [-6.59, -3.01]	4.18
P M O'Neil et al. (2018) D	-4.83 [-7.93, -1.73]	2.99
T. Kadowaki et al. / 2022 (STEP 6) A —	-5.92 [-8.87, -2.97]	3.11
Wilding et al. (2021)	-5.94 [-7.92, -3.96]	4.00
T. Kadowaki et al. / 2022 (STEP 6) B —	-6.28 [-9.69, -2.87]	2.73
H. Rodbard et al. (2018) / (SUSTAIN 5) B —	-6.30 [-9.92, -2.68]	2.58
F. Knop et al. / 2023 (OASIS 1)	-6.30 [-8.16, -4.44]	4.12
P M O'Neil et al. (2018) G	-8.68 [-11.75, -5.61]	3.01
Heterogeneity: τ² = 1.45, Ι² = 58.85%, Η² = 2.43	-4.23 [-5.02, -3.44]	
Test of $\theta_i = \theta_i$: Q(19) = 46.17, p = 0.00	i i	
Test of $\theta = 0$: z = -10.55, p = 0.00		
Overall	-3.40 [-4.22, -2.59]	
Heterogeneity: $\tau^2 = 3.31$, $I^2 = 87.78\%$, $H^2 = 8.18$		
Test of $\theta_i = \theta_j$: Q(31) = 253.59, p = 0.00		
Test of $\theta = 0$: z = -8.17, p = 0.00		
Test of group differences: $Q_b(1) = 57.54$, p = 0.00		

Study		Mean diff. with 95% Cl	Weight (%)
120-129 mmHg			
Garvey et al. (2022) /(STEP 5 Trial)		-2.40 [-5.46, 0.66]	3.06
Wilding et al. (2021)		-5.94 [-7.92, -3.96]	3.96
F. Knop et al. / 2023 (OASIS 1)		-6.30 [-8.16, -4.44]	4.06
Heterogeneity: $\tau^2 = 2.09$, $I^2 = 61.90\%$, $H^2 = 2.62$	•	-5.19 [-7.28, -3.09]	
Test of $\theta_i = \theta_j$: Q(2) = 4.84, p = 0.09			
Test of θ = 0: z = -4.85, p = 0.00			
130-139 mmHg			
I Lingvay et al. (2018) A	•	0.02 [-0.56, 0.60]	4.91
I Lingvay et al. (2018) B		-0.28 [-0.87, 0.31]	4.91
l Lingvay et al. (2018) C		-0.58 [-1.14, -0.02]	4.92
I Lingvay et al. (2018) D		-0.78 [-1.36, -0.20]	4.91
M Davies et al. (2017) A		-2.70 [-7.05, 1.65]	2.19
Kosiborod et al. (2023) / (STEP HFpEF trial)		-2.90 [-7.07, 1.27]	2.29
M Davies et al. (2017) F		-3.00 [-7.63, 1.63]	2.03
Gullaksen et al. (2023)		-3.30 [-11.98, 5.38]	0.82
A. M. Lincoff (2023) /SELECT Trial		-3.31 [-3.75, -2.87]	4.96
M Davies et al. (2017) E		-3.40 [-8.00, 1.20]	2.05
M Davies et al. (2017) D		-3.50 [-8.10, 1.10]	2.05
M Davies et al. (2017) B		-3.90 [-8.28, 0.48]	2.17
M. Davies et al. / 2021 (STEP 2)		-4.80 [-6.59, -3.01]	4.12
M Davies et al. (2017) C		-5.10 [-9.48, -0.72]	2.17
T. Kadowaki et al. / 2022 (STEP 6) A		-5.92 [-8.87, -2.97]	3.15
T. Kadowaki et al. / 2022 (STEP 6) B		-6.28 [-9.69, -2.87]	2.79
Heterogeneity: τ^2 = 3.56, I ² = 93.00%, H ² = 14.30	◆ 1	-2.66 [-3.84, -1.48]	
Test of $\theta_i = \theta_j$: Q(15) = 158.82, p = 0.00			
Test of θ = 0: z = -4.43, p = 0.00			
Test of group differences: $Q_b(1) = 4.24$, p = 0.04			
	-10 -5 0 Favour GLP-1RA Favour P	5 Placebo	

	Mean diff.	Weigh
	with 95% CI	(%)
Non-DM Cohort	_	
P M O'Neil et al. (2018) A	-2.88 [-5.99, 0.23]	3.02
P M O'Neil et al. (2018) B	-4.18 [-7.27, -1.09]	3.04
P M O'Neil et al. (2018) C	-4.68 [-7.78, -1.58]	3.03
P M O'Neil et al. (2018) D -	-4.83 [-7.93, -1.73]	3.03
P M O'Neil et al. (2018) E	-4.23 [-7.30, -1.16]	3.05
P M O'Neil et al. (2018) F	-4.49 [-7.59, -1.39]	3.03
P M O'Neil et al. (2018) G	-8.68 [-11.75, -5.61]	3.06
Vilding et al. (2021)	-5.94 [-7.92, -3.96]	3.96
A. M. Lincoff (2023) /SELECT Trial	-3.31 [-3.75, -2.87]	4.96
Kosiborod et al. (2023) / (STEP HFpEF trial)	-2.90 [-7.07, 1.27]	2.29
Garvey et al. (2022) /(STEP 5 Trial)	-2.40 [-5.46, 0.66]	3.06
. Knop et al. / 2023 (OASIS 1)	-6.30 [-8.16, -4.44]	4.06
leterogeneity: τ² = 1.40, l² = 55.26%, H² = 2.24	-4.60 [-5.61, -3.59]	
Test of $\theta_i = \theta_j$: Q(11) = 27.97, p = 0.00	l l	
Test of $\theta = 0$: z = -8.93, p = 0.00		
Pure DM Cohort		
1. Davies et al. / 2021 (STEP 2)	-4.80 [-6.59, -3.01]	4.12
Lingvay et al. (2018) A	0.02 [-0.56, 0.60]	4.91
Lingvay et al. (2018) B	-0.28 [-0.87, 0.31]	4.91
Lingvay et al. (2018) C	-0.58 [-1.14, -0.02]	4.92
Lingvay et al. (2018) D	-0.78 [-1.36, -0.20]	4.91
Sorli et al. (2017)/ SUSTAIN 1 A	-0.86 [-3.39, 1.67]	3.49
C Sorli et al. (2017)/ SUSTAIN 1 B	-1.02 [-3.53, 1.49]	3.51
I. Rodbard et al. (2018) / (SUSTAIN 5) A	-3.30 [-6.91, 0.31]	2.66
I. Rodbard et al. (2018) / (SUSTAIN 5) B	-6.30 [-9.92, -2.68]	2.65
Gullaksen et al. (2023)	-3.30 [-11.98, 5.38]	0.82
Mosenzon et al. (2019) / (PIONEER 5)	-7.00 [-20.85, 6.85]	0.36
1 Husain et al. (2019) / PIONEER 6	-3.00 [-4.25, -1.75]	4.54
I Davies et al. (2017) A	-2.70 [-7.05, 1.65]	2.19
I Davies et al. (2017) B	-3.90 [-8.28, 0.48]	2.17
1 Davies et al. (2017) C	-5.10 [-9.48, -0.72]	2.17
1 Davies et al. (2017) D	-3.50 [-8.10, 1.10]	2.05
1 Davies et al. (2017) E	-3.40 [-8.00, 1.20]	2.05
A Davies et al. (2017) F	-3.00 [-7.63, 1.63]	2.03
Heterogeneity: τ ² = 2.51, l ² = 86.33%. H ² = 7.31	♦ -2.15 [-3.141.15]	
Test of $θ_i = θ_i$: Q(17) = 63.87. p = 0.00	· · · · · · · · · · · · · · · · · · ·	
iest of $\theta = 0$: z = -4.20, p = 0.00		
est of group differences: $Q_b(1) = 11.49$, p = 0.00		

Random-effects REML model

medRxiv preprint doi: https://doi.org/10.110 (which was not certified by peer revi	01/2024 ew) is t	he auth	243019 hor/fund	71; this er, who	versior has gra	n poste anted n	d January 30, 202 nedRxiv a license	4. The copyright holder f to display the preprint in	or this prep perpetuity.	orint Weight
Study	Total	Mean	SD	Total	Mean	SD SD		with 95	% CI	(%)
24 weeks or more										()-)
Jorsal et al. (2016)/(LIVE)	122	-4	12	119	-2	16		-2.00 [-5.	56. 1.56]	2.98
J. Loganathan et al. (2022)/ (ELAID)	7	-3	12	9	1	15		-4.00 [-17.	63, 9.63]	0.38
T. Deigaard et al. (2019)/ (Lira Pump)	22	-6.6	14.7	22	-2.5	13.9		-4.10 [-12.	55, 4.35]	0.89
P M O'Neil et al. (2018)	103	-5.45	11.98	136	-1.58	12.13		-3.87 [-6.	960.781	3.41
H. Ghanim et al. (2020)	42	-5	3	42	-4	2	_	-1.00 [-2.	09. 0.091	5.49
C. le Boux et al. (2017)	1.505	-3.2	13	749	- 5	13.7	—	-2.70 [-3	861.54]	5.43
P Kumarathurai et al. (2016)	19	-8.1	17.27	20	-3.17	16.07		-4.93[-15	39 5 53	0.61
P Kumarathurai et al. (2021)	19	-8.1	17.27	20	-3.17	16.07		-4.93 [-15	39 5.53	0.61
C A Whicher et al. (2021)	24	-3	14	23	-6	17		3.00 [-5.	89, 11,89]	0.82
M. Davies et al. (2015) / (SCALE Diabetes) A	412	-2.8	13.5	211	- 4	13.4		-2.40 [-4	630.171	4.30
M. Davies et al. (2015) / (SCALE Diabetes) B	204	-3.5	12.7	211	- 4	13.4		-3.10 [-5.	610.59]	3.99
H M de Wit et al. (2014) / (ELEGANT)	26	-7	2	24	-3	3	i	-4.00 [-5.	402.60]	5.20
J Miyagawa et al. (2015) B	141	-2.1	.89	70	53	1.25		-2.63 [-2	92 -2.341	5.98
J B Lundren et al. (2021)	49	-1.1	15.36	49	4.4	15.54		-5.50 [-11	62. 0.621	1.50
X Pi-Sunver et al. (2015)	2 437	-4.2	12.2	1.225	-1.5	12.4		-2.70 [-3	54 -1.86]	5.69
R M Sandedal et al. (2023)	49	-1	15 71	1,220	4.2	15.89		-5.20 [-11	46 1.06]	1 45
T & Wadden et al. (2019) &	-+9 50	-12	2 1	50	-13.6	2 1		-5.20[-11.	78 2 4 21	5.71
TA Wadden et al. (2019) A	50	-12 3	2.1	50	-14.1	2.1	_	0.80[-0.	02 1 62	5.71
Mok et al. (2013) / (BARLOPTIMISE)	35	- 13.3	16.4	35	2 24	18.03		0.60 [-0.	02, 1.02]	0.02
M Lind et al. (2015) / (MDLL isoclutide trial)	64	-0.20	10.4	60	1.01	10.55		-0.02 [-10.	52, -0.32]	0.92
M. Lind et al. (2015) / (MDI Linagiulide thai)	04	-5.02	12.90	00	1.91	13.11		-6.93[-11.	52, -2.34j	2.23
M J Armstrong et al. (2006) / (LEAN trial)	20	-5	13.4	20	-3	14	A 1	-2.00[-9.	+0, 0.40j	1.10
Heterogeneity: t = 3.37, I = 87.88%, H = 8.25								-2.35 [-3.	44, -1.25]	
Test of $\theta_i = \theta_i$: Q(20) = 164.22, p = 0.00										
lest of $\theta = 0$: $z = -4.20$, $p = 0.00$										
less than 24 weeks							1			
T Idorn (2016) A	10	-3.6	32.89	10	-3.6	10.20		0.00[-23	ES 23 ESI	0 13
T Idom (2016) B	10	-3.1	12.33	10	-7.4	16 13		4 30 [-8	28 16 88]	0.44
S Kim et al. (2013)	24	-8.1	11 1	27	-2.6	10.15		-5 50 [-11	02 0.021	1 75
P. Kumarathurai et al. (2017)	24	-1.4	8.1	24	-3.2	11 1			70 7 301	1.76
B Faber et al. (2015)	10	-5	9	10	5	12		-10.00 [-19	30 -0 70]	0.76
W Chen et al. (2015)	45	-13	57	45	-15	39.4		2 00 [-18	25 22 25]	0.18
N Kubadiya et al (2016) A	14	-10	4 1	17	-15	20	_	-2 50 [-4	97 -0.031	4.04
N. Kuhadiya et al (2016) R	16	-1.5	4.1	17	5	2.5	_	-2.50 [-4.	37 1 37	4.14
N. Kuhadiya et al (2016) C	16	-1.5	4	17	5	2.9		-2.80 [-5.	33 .0 271	3.08
P. Mensherr et al. (2016)	17	-3.3	7.4	16	5	11.1		-2.80 [-5.	20, 1, 60]	1.40
P. Mensberg et al. (2016)	17	-5.4	10	10	0	11.1		-4.80 [-11.	20, 1.00]	1.40
N. Matikainen et al. (2016)	10	4 70	7.06	21	-0	7 07		= 12.00[1.	51, 22.19j	0.64
A Liakos et al. (2018)	31	-4.72	10.70	51	1.02	10.70		-5.74[-9.	71, -1.77]	2.00
J Larsen et al. (2017)	47	-1.4	13.72	50	1.1	12.73	1	-2.50[-7.	/6, 2./6]	1.87
A. Bojer et al. (2021)	20	-1.6	8.9	20	8	11.6		-0.80[-7.	21, 5.61]	1.40
A Astrup et al. (2009) A	95	-12.8	14.4	98	-7.8	15		-5.00[-9.	15, -0.85]	2.53
A Astrup et al. (2009) B	90	-10.7	13.6	98	-7.8	15		-2.90[-7.	JI, 1.21]	2.56
A Astrup et al. (2009) C	93	-14.7	12	98	-7.8	15		-6.90[-10.	77, -3.03]	2.74
A Astrup et al. (2009) D	93	-13.3	13.2	98	-7.8	15		-5.50 [-9.	52, -1.48]	2.62
Heterogeneity: $\tau^{-} = 1.78$, $\Gamma^{-} = 26.18\%$, $H^{-} = 1.35$								-3.11 [-4.	40, -1.83]	
lest of $\theta_i = \theta_i$: Q(17) = 27.63, p = 0.05										
Test of $\theta = 0$: z = -4.74, p = 0.00										
Quere II										
							· · · · ·	-2.61[-3.	+6, -1./4]	
Heterogeneity: $\tau^{-} = 3.24$, $\Gamma^{-} = 80.46\%$, $H^{-} = 5.12$										
lest of $\theta_i = \theta_j$: Q(38) = 195.26, p = 0.00										
lest of $\theta = 0$: $z = -5.91$, $p = 0.00$										
Test of group differences: $\boldsymbol{Q}_{_{b}}(1)$ = 0.79, p = 0.38										
							-20 -10 0	10 20		
Random-effects REML model						Fav	vour GLP-1RA Fa	avour Placebo		

	GLP-1RA		Placebo				Mean diff.	Weight	
Study	Total	Mean	SD	Total	Mean	SD		with 95% CI	(%)
24 weeks or more							i		
K.M. Dungan et al. (2016) / AWARD-8	239	52	.96	60	0	1.54		-0.52 [-0.83, -0.21]	14.13
H. Gerstein et al. (2019) / REWIND	4,949	-3.15	9.1	4,952	-1.44	9.1		-1.71 [-2.07, -1.35]	14.01
K C Ferdinand et al (2014) A	251	-2.5	9.5	250	.2	9.49		-2.70 [-4.36, -1.04]	8.38
K C Ferdinand et al (2014) B	254	-1.6	9.56	250	.2	9.48	- -	-1.80 [-3.46, -0.14]	8.38
J Miyagawa et al (2015) A	281	.62	.62	70	.53	1.25		0.09 [-0.12, 0.30]	14.33
Heterogeneity: $\tau^2 = 0.96$, $I^2 = 95.90\%$, $H^2 = 24.41$							◆	-1.14 [-2.09, -0.19]	
Test of $\theta_i = \theta_j$: Q(4) = 83.61, p = 0.00							i		
Test of θ = 0: z = -2.35, p = 0.02							i		
							i		
less than 24 weeks							i		
G Grunbderger (2012) A	35	-2.2	13.02	32	7	12.45	- i	-1.50 [-7.61, 4.61]	1.33
G Grunbderger (2012) B	34	.5	12.24	32	7	12.45	i	1.20 [-4.76, 7.16]	1.40
G Grunbderger (2012) C	34	-2.6	11.66	32	7	12.45		-1.90 [-7.72, 3.92]	1.46
G Grunbderger (2012) D	29	1.9	12.4	32	7	12.45		2.60 [-3.64, 8.84]	1.28
K C Ferdinand et al (2014) A	251	-3.7	9.5	250	3	7.91		-3.40 [-4.93, -1.87]	8.95
K C Ferdinand et al (2014) B	254	-1.9	7.97	250	3	7.91		-1.60 [-2.99, -0.21]	9.61
K C Ferdinand et al (2014) C	251	-3.4	9.5	250	6	9.49		-2.80 [-4.46, -1.14]	8.38
K C Ferdinand et al (2014) D	254	-1.7	9.56	250	6	9.49	- -	-1.10 [-2.76, 0.56]	8.37
Heterogeneity: $\tau^2 = 0.46$, $I^2 = 25.79\%$, H	² = 1.35						•	-2.00 [-2.97, -1.03]	
Test of $\theta_i = \theta_j$: Q(7) = 8.73, p = 0.27							i		
Test of θ = 0: z = -4.03, p = 0.00							i		
Overall							•	-1.46 [-2.20, -0.72]	
Heterogeneity: $\tau^2 = 0.99$, $I^2 = 89.78\%$, H	² = 9.78						i i		
Test of $\theta_i = \theta_j$: Q(12) = 110.08, p = 0.00							i i		
Test of $\theta = 0$: z = -3.86, p = 0.00							i		
Test of group differences: $Q_b(1) = 1.52$, p	o = 0.22						i		
						۔ 1-1	0 -5 0	5 10	
Random-effects REML model						Fa	vour GLP-1RA	Favour Placebo	